Psoriatic Arthritis Market to Reach USD 12.2 Billion by 2034

Psoriatic arthritis (PsA) is a chronic, inflammatory musculoskeletal disorder associated with psoriasis, affecting joints, tendons, and ligaments. It causes joint pain, swelling, stiffness, and progressive disability if left untreated. Globally, psoriatic arthritis represents a growing healthcare challenge, as up to 30% of psoriasis patients eventually develop PsA.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71531

With increasing prevalence, better screening programs, and advances in biologic and targeted therapies, the PsA treatment landscape has improved significantly. From TNF inhibitors to IL-17 and IL-23 blockers, therapeutic innovation is reshaping disease management. Between 2024 and 2034, the psoriatic arthritis market is expected to expand steadily, fueled by rising diagnosis rates, personalized medicine, and broader access to advanced biologics.

Market Overview
The global psoriatic arthritis market size in 2024 is estimated at USD 5.6 billion and is projected to reach USD 12.2 billion by 2034, growing at a CAGR of 8.1% over the forecast period.

Key highlights:
• Rising prevalence of psoriasis and psoriatic arthritis worldwide.
• Increased adoption of biologic therapies (TNF, IL-17, IL-23 inhibitors).
• Expansion of oral small molecules (JAK inhibitors, PDE4 inhibitors) for moderate-to-severe cases.
• Growing role of digital health platforms and tele-rheumatology in patient management.
• North America and Europe dominate today, but Asia-Pacific is projected to grow fastest.

Market Segmentation
By Product
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Conventional DMARDs (Methotrexate, Sulfasalazine, Leflunomide)
• Biologics (TNF Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors)
• Targeted Synthetic DMARDs (JAK Inhibitors, PDE4 Inhibitors)
• Others

By Technology
• Biologics
• Small-Molecule Targeted Therapies
• Conventional Systemic Therapies

By Platform
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End Use
• Hospitals & Specialty Clinics
• Ambulatory Care Centers
• Homecare Settings

By Application
• Mild Psoriatic Arthritis
• Moderate Psoriatic Arthritis
• Severe Psoriatic Arthritis

Summary of Segmentation
Biologics remain the gold standard for moderate-to-severe PsA, while targeted synthetic DMARDs like JAK inhibitors are emerging rapidly. Conventional DMARDs and NSAIDs continue to serve mild cases. Hospitals and specialty clinics dominate patient care, but online pharmacies are gaining ground as biologics and oral therapies expand into homecare.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71531/psoriatic-arthritis-market

Regional Analysis
North America
• Largest market in 2024 due to high prevalence, advanced rheumatology infrastructure, and strong adoption of biologics.
• The U.S. leads with wide insurance coverage and a strong pipeline of innovative therapies.
Europe
• Second-largest share, led by Germany, the UK, France, and Italy.
• High biologic penetration supported by government reimbursement systems.
Asia-Pacific
• Expected to record the fastest CAGR through 2034.
• Rising prevalence of psoriasis and PsA in China, India, and Japan.
• Expanding access to biosimilars improves affordability of advanced treatments.
Middle East & Africa
• Limited adoption today, but gradual improvements with specialized rheumatology centers.
• Increasing awareness and diagnosis expected in urban areas.
Latin America
• Brazil and Mexico dominate with rising demand for biologics and small-molecule therapies.
Regional Summary
While North America and Europe dominate in adoption and revenue, Asia-Pacific is the next major growth hub, driven by rising prevalence, better screening, and affordability of biosimilars.

Market Dynamics
Growth Drivers
• Rising global prevalence of psoriasis and psoriatic arthritis.
• Increased adoption of biologics and targeted small molecules.
• Growing awareness and earlier diagnosis through screening initiatives.
• Expansion of biosimilars improving affordability and access.

Key Challenges
• High cost of biologics in low- and middle-income regions.
• Side effects and long-term safety concerns for targeted therapies.
• Limited access to rheumatology specialists in developing countries.
• Patient adherence issues with chronic treatment regimens.

Latest Trends
• Expansion of IL-17 and IL-23 inhibitors as next-generation biologics.
• Introduction of JAK inhibitors for oral convenience and targeted efficacy.
• Growth of tele-rheumatology and digital platforms for patient monitoring.
• Rising use of real-world evidence (RWE) to evaluate long-term safety and effectiveness.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71531

Competitive Landscape
Major Players
• AbbVie Inc. (Humira, Rinvoq, Skyrizi)
• Novartis AG (Cosentyx)
• Johnson & Johnson (Stelara, Tremfya)
• Eli Lilly and Company (Taltz)
• Bristol-Myers Squibb (Orencia, TYK2 pipeline)
• Pfizer Inc. (Xeljanz)
• Amgen Inc. (Enbrel, Otezla)
• UCB Pharma (Bimzelx, Cimzia)
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Gilead Sciences
• Roche Holding AG

Competition Summary
The psoriatic arthritis market is highly competitive, with AbbVie, Novartis, and Johnson & Johnson leading due to their blockbuster biologics. Eli Lilly and Amgen also have strong footholds with targeted therapies. The market is seeing increased competition from biosimilars and next-generation oral small molecules, making innovation and affordability key strategic priorities.

Conclusion
The psoriatic arthritis market is entering a growth phase fueled by biologic innovation, earlier diagnosis, and expansion of biosimilars. By 2034, the market is expected to nearly double in size, supported by rising prevalence and broader therapy access.

While challenges such as treatment costs and adherence remain, opportunities lie in precision medicine, tele-rheumatology, and emerging markets. For pharmaceutical companies, rheumatology centers, and healthcare providers, PsA represents a rapidly evolving and high-potential therapeutic area.

Key Takeaways:
• Biologics dominate moderate-to-severe PsA, but targeted small molecules are expanding treatment options.
• North America and Europe lead adoption, while Asia-Pacific will see the fastest growth.
• Biosimilars and affordability initiatives will be crucial for market expansion.
• Innovation, patient access, and digital health integration will define long-term success.

This report is also available in the following languages : Japanese (乾癬性関節炎市場), Korean (건선성 관절염 시장), Chinese (银屑病关节炎市场), French (Marché de l'arthrite psoriasique), German (Markt für Psoriasis-Arthritis), and Italian (Mercato dell'artrite psoriasica), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71531/psoriatic-arthritis-market#request-a-sample

Our More Reports:

Acute ischemic stroke Market
https://exactitudeconsultancy.com/reports/71890/acute-ischemic-stroke-market

Acute Pancreatitis Market
https://exactitudeconsultancy.com/reports/71891/acute-pancreatitis-market

Acute Social Anxiety Disorder Market
https://exactitudeconsultancy.com/reports/71892/acute-social-anxiety-disorder-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.